Monopar Therapeutics stock price target raised to $104 by BTIG

Investing.com - BTIG raised its price target on Monopar Therapeutics (NASDAQ:MNPR) to $104.00 from $87.00 on Wednesday, while maintaining a Buy rating on the stock. The company, currently valued at $451.52 million, has seen its shares surge over 200% year-to-date, recently touching new 52-week highs.

The price target increase follows Monopar’s announcement of a published letter to the editor in the Journal of Hepatology by leading Wilson’s disease key opinion leaders (KOLs), which detailed an updated copper balance analysis from the Phase 2 copper balance study conducted by AstraZeneca (NASDAQ:AZN). According to InvestingPro data, analyst targets for MNPR now range from $52 to $130, with a strong buy consensus.

According to BTIG, the authors’ analysis provides external validation of Monopar’s view that AstraZeneca’s copper balance calculation was flawed, with patient-by-patient data showing consistent negative trends in copper balance for a majority of patients. While the company maintains strong liquidity with a current ratio of 33.94, InvestingPro analysis suggests the stock is currently trading above its Fair Value.

BTIG believes this update provides Monopar with solid data to discuss with the FDA as the company prepares for a New Drug Application (NDA) in early 2026.

The firm stated that this development supports their increased probability of success for ALXN1840, Monopar’s drug candidate, which drove the new $104 price target.

In other recent news, Monopar Therapeutics announced a significant stock offering expected to generate approximately $100 million in gross proceeds. This offering includes over a million shares of common stock and pre-funded warrants, each priced at around $67.67. Meanwhile, H.C. Wainwright reiterated a Buy rating on Monopar with a $70 price target, citing positive long-term data for their Wilson disease treatment, ALXN1840. BTIG also initiated coverage with a Buy rating and a higher price target of $87, focusing on Monopar’s development of the novel copper-binding therapy for Wilson’s Disease. Cantor Fitzgerald maintained its Overweight rating and a $74 price target, highlighting the continued support from the ALXN team for Monopar’s drug development. Additionally, H.C. Wainwright initiated coverage with a Buy rating and a $70 price target, emphasizing the misunderstood potential of ALXN1840 despite its demonstrated benefits in Phase 3 trials. These developments reflect a broad interest in Monopar’s therapeutic advancements and financial strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.